A Study evaluating Infliximab and Adalimumab Trough Level and Anti-Drug Antibody Measurements in Finnish patients with rheumatoid arthritis , spondyloarthropathies , or juvenile idiopathic arthritis
Latest Information Update: 01 Jul 2017
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary)
- Indications Juvenile rheumatoid arthritis; Rheumatic disorders; Rheumatoid arthritis; Spondylarthritis
- Focus Pharmacodynamics; Pharmacokinetics
- 01 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism